Schrödinger, Inc. SDGR

Company Overview

Schrödinger, Inc. is a life sciences and software company that develops physics-based computational platforms to accelerate drug discovery and materials science research. The company operates at the intersection of biotechnology, pharmaceuticals, and advanced scientific software, providing tools that enable researchers to model, simulate, and predict molecular behavior with high precision. Its core value proposition is reducing the time, cost, and failure rates associated with traditional experimental approaches in drug development.

The company’s primary revenue drivers are its Software business, which licenses its computational chemistry and molecular modeling platforms, and its Drug Discovery business, which applies those platforms to develop proprietary and partnered therapeutic candidates. Schrödinger serves pharmaceutical companies, biotechnology firms, academic institutions, and industrial research organizations. Founded in 1990, the company was built around academic advances in computational chemistry and has evolved from a pure software provider into a hybrid platform company with an integrated drug discovery pipeline, culminating in its public listing in 2020.